Forbes, Novartis deal
This article was originally published in The Tan Sheet
Executive Summary
Forbes Medi-Tech, Novartis plan to close a deal in the "very near future" resolving conflict over Master License Agreement, Forbes President & CEO Charles Butt says in Q1 conference call May 31. Firms had "very productive" meeting in May to resolve disagreement over 1999 MLA; Forbes had claimed Novartis failed to comply with MLA, said it would not pay $4 mil. to buy back Reducol rights (1"The Tan Sheet" March 25, 2002, In Brief). Butt also says Vancouver-based firm has "no immediate plans" to sell off its nutraceuticals, functional food business. In May 30 release, Forbes notes it needs "additional debt or equity financing by September 30, 2002 to meet its planned expenditures"...
You may also be interested in...
Reducol rights
Forbes Medi-Tech's ability to sell its Phytrol (Reducol) phytosterol ingredient is "materially affected" by Novartis' noncompliance with terms of 1999 Master License Agreement, firm says March 18. Without detailing alleged noncompliance, Forbes notes it was "surprised" by Novartis' and Quaker's termination of Altus Foods joint venture, says Novartis' actions have led to delayed market introduction of certain Phytrol-containing foods. Forbes will not pay $4 mil. to buy back licensing, distribution rights for Reducol, as previously announced, but has notified Novartis it is terminating the MLA. Consequently, all rights to the ingredient, except for the Reducol name, would revert to Forbes on June 18 unless Novartis corrects noncompliance, Forbes says. Novartis believes it has complied with MLA, seeks amicable resolution...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.